Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particularly prescient in light of the cost and supply constraints threatening many biotechs today. On this episode of The BioCentury Show, Editor in Chief Simone Fishburn sits down with Oyler to discuss the early strategies that are now paying off for the global oncology company.
View full story: https://www.biocentury.com/article/653597
#biotech #biopharma #pharma #lifescience #drugdevelopment
00:00 - Introduction
11:20 – In-house Manufacturing
15:51 – BeiGene’s Pipeline
23:45 – Partnering Plans
27:00 – Building a High Value Biotech
The BioCentury Show